Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2025-02-01 Call Transcript
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on 30 January 2025 discussing the financial results for the quarter and nine months ended 31 December 2024. It includes detailed management commentary on financial performance, operational updates, and a Q&A session with investors. The presence of a moderator, management speakers, and investor questions confirms it is a full call transcript. The document is lengthy (15,000 characters) and contains substantive financial discussion, not just an announcement or summary. Therefore, it fits the definition of a Call Transcript (CT).
2025-02-01 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges submitting newspaper clippings of an extract of unaudited consolidated financial results for the quarter and nine months ended 31 December 2024. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document is short (1193 characters) and does not contain the full financial results or detailed financial statements, but rather an extract published in newspapers. This fits the profile of a Regulatory Filing (RNS) as it is a compliance disclosure and not the full financial report itself. It is not an Interim/Quarterly Report (IR) because it lacks substantive financial data and analysis, and it is not an Earnings Release (ER) because it is not an initial announcement but a submission of published extracts. Therefore, the best classification is Regulatory Filings (RNS).
2025-01-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement informing about the availability of the audio recording of the company's earnings conference call for the quarter and nine months ended 31 December 2024. It references the earnings call but does not contain the transcript or financial data itself. The document length is only 1086 characters, indicating it is an announcement rather than the full call transcript. According to the rules, announcements about availability of call recordings or transcripts should be classified as Regulatory Filings (RNS) because they do not contain the full transcript or substantive financial data.
2025-01-30 English
Integrated Filing- Financial
Regulatory Filings
2025-01-30 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is dated 30 January 2025 and is addressed to stock exchanges (BSE and NSE) with a subject about the outcome of a Board Meeting and submission of unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024. It includes detailed financial data for Q3 and 9M FY25, including revenues, divisional sales, profitability metrics (EBITDA, PAT), and EPS, both standalone and consolidated. The document also contains management commentary on business segments, outlook, and operational highlights. The presence of unaudited financial results for a quarter and nine months period, with substantive financial data and analysis, aligns with the characteristics of an Interim / Quarterly Report. It is not a brief announcement or a certification letter, nor is it a full annual report or earnings release summary. Therefore, the document is best classified as an Interim / Quarterly Report (IR).
2025-01-30 English
Financial Result Updates
Regulatory Filings
2025-01-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.